Boston Scientific Acquires Penumbra at $374 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Source: Benzinga
- Acquisition Deal: Boston Scientific has agreed to acquire Penumbra at $374 per share, valuing the transaction at approximately $14.5 billion, indicating strong interest in the medical device market and expected to enhance Boston Scientific's product portfolio and market share.
- Shareholder Options: Penumbra shareholders can choose between cash or Boston Scientific stock, with an overall proration of about 73% cash and 27% equity, which may attract more investor participation and enhance shareholder satisfaction.
- Strong Performance: Penumbra's preliminary fourth-quarter results exceeded expectations, with shares rising 12.1% to $351.25 on Thursday, reflecting market confidence in its future growth potential and likely boosting investor sentiment further.
- Market Reaction: The acquisition news significantly boosted Penumbra's stock price, demonstrating a positive market response to M&A activities in the healthcare sector, which may also trigger similar acquisition activities among other related companies, further energizing the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 48.700
Low
94.00
Averages
108.14
High
132.00
Current: 48.700
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology and vascular therapies (ICVT), watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Initiates $2 Billion Share Repurchase Agreement
- Share Repurchase Program: Boston Scientific has entered into an accelerated share repurchase agreement with JPMorgan to buy back $2 billion of its common stock, part of a previously authorized $5 billion program, reflecting the company's confidence in its stock value.
- Share Count and Value: The company will immediately receive approximately 30.4 million shares, representing 80% of the repurchase value based on the May 15 closing price, effectively reducing the number of shares in circulation and enhancing earnings per share.
- Financial Impact: This repurchase is expected to add $0.02 to the adjusted earnings per share by 2026, improving the financial guidance previously issued in April, indicating a proactive capital allocation strategy.
- Strategic Goals: By reducing the share count, Boston Scientific aims to deliver greater value to shareholders while maintaining resources to support its ongoing operational and strategic objectives, showcasing its long-term growth potential in the medical device sector.
See More
Boston Scientific and Others Face Stock Declines Amid Market Concerns
- Boston Scientific Stock Decline: Boston Scientific (BSX) shares fell to a 52-week low of $47.35 due to growing concerns over its U.S. Watchman heart-device franchise, with analysts cutting the price target to $70, reflecting anticipated slowdowns in 2026 and 2027 that negatively impact revenue and earnings.
- Lowe's Faces Weaker Growth Outlook: Lowe's (LOW) shares dropped to a new low of $207.55 as weaker growth expectations and a sluggish housing market weighed on prospects, despite first-quarter results beating estimates; high mortgage rates and inflation pressures continue to challenge the company.
- Conagra Brands New CEO Appointment: Conagra (CAG) shares hit a 52-week low of $13.10 amid investor concerns over growth prospects and profitability, as new CEO John Brase takes over, facing persistent inflation and weak consumer demand for packaged foods.
- Market Sentiment Shift: Despite BSX's stock dropping over 49%, retail sentiment on Stocktwits remains in the 'extremely bullish' territory, while Lowe's and CAG experience fluctuating sentiments due to market pressures, indicating cautious investor attitudes towards future performance.
See More
Boston Scientific Shares Hit 52-Week Low Amid Weak Growth Outlook
- Boston Scientific Stock Decline: Boston Scientific shares fell to a 52-week low of $48.13, experiencing a 16% weekly drop due to weak expectations for its Watchman heart device business, with management indicating that U.S. revenue may remain weak for the next two quarters, prompting analysts to lower price targets.
- Li Auto's Profitability Pressure: Li Auto reported weaker profits in its Q1 earnings, forecasting Q2 deliveries between 95,000 and 100,000 vehicles, reflecting soft demand and intense competition in China's EV market, leading Barclays to cut its price target from $18 to $14, implying nearly a 7% downside.
- Rollins Valuation Reset: Rollins reached a new low of $46.85 despite solid operating performance, as investors focused on valuation concerns, with Bernstein downgrading the stock and lowering its price target from $70 to $52, citing the potential negative impact of CFO Ken Krause's departure on profitability.
- Market Sentiment Shift: The stocks of Boston Scientific and Rollins have declined over 49% and 20% respectively this year, while Li Auto has shed over 11%, indicating a shift in investor confidence away from premium-priced growth stocks, with market sentiment changing from 'extremely bullish' to 'bullish'.
See More
Boston Scientific Shares Drop 15% Amid Analyst Downgrades
- Product Line Weakness: Boston Scientific acknowledged potential stagnation in sales of its Watchman heart implant line, contributing to a 15% drop in stock price this week, reflecting market concerns about future growth prospects.
- Analyst Downgrades: Wells Fargo analyst Lawrence Biegelsen downgraded Boston Scientific's rating from overweight to equal weight and reduced the price target from $75 to $55, indicating a pessimistic outlook on the company's future performance.
- Revenue Growth Guidance: Despite facing challenges, Boston Scientific maintained its guidance for organic revenue growth of 6.5% to 8% for 2026, demonstrating confidence in long-term growth potential.
- Increased Market Competition: Analysts noted that new drugs under development by pharmaceutical companies could heighten competitive pressure, particularly in other product categories like urology, further impacting the company's market position.
See More
Boston Scientific Shares Plummet Amid Weak Product Forecast
- Product Line Weakness: Boston Scientific CEO Mike Mahoney indicated at Bernstein's Annual Strategic Decisions Conference that sales of the Watchman heart implants may stagnate, with revenue expected to remain flat in both the current and following quarters, reflecting a shift in market demand away from standalone procedures, which could impact overall performance.
- Analyst Downgrades: Amid increasing pessimism, Wells Fargo analyst Lawrence Biegelsen downgraded the stock from overweight to equal weight and reduced the price target from $75 to $55, highlighting concerns over the new Watchman forecast and weakness in other product lines, such as urology.
- Significant Market Reaction: As of early Friday morning, Boston Scientific's shares had dropped by 15%, reflecting investor concerns about the company's future growth potential, particularly in the face of increasing competition that could affect its market share.
- Positive Long-Term Outlook: Despite short-term challenges, Boston Scientific maintained its guidance for organic revenue growth of 6.5% to 8% for 2026, indicating the company's long-term potential in the medical device sector, suggesting that investors may view this week's stock decline as an opportunity to acquire quality shares at a discount in a vibrant industry.
See More
Boston Scientific Faces Pressure Amid Weak Watchman Procedures
- Boston Scientific's Decline: CEO Michael Mahoney indicated that standalone Watchman procedures are weakening, leading to a 12% stock drop on Wednesday, hitting a two-year low of $50.04, which underscores the growth pressures in the medical device market.
- Li Auto's Loss Expectations: Li Auto's stock reached a 52-week low of $15.3 ahead of its earnings report, with analysts forecasting a RMB2.08 ($0.31) per-share loss, highlighting the intensified competition and price declines in China's EV market impacting profitability.
- BJ's Wholesale Earnings Outlook: BJ's Wholesale Club faced selling pressure as investors questioned its near-term earnings, with a 10-basis-point decline in merchandise margins in Q1, prompting DA Davidson to lower its price target to $105 while maintaining a 'Buy' rating, indicating challenges in the retail sector.
- Market Sentiment Shift: Despite Boston Scientific, Li Auto, and BJ's stocks hitting new 52-week lows, retail sentiment shifted from 'bearish' to 'bullish', reflecting investor expectations for potential rebounds in the near future.
See More
Boston Scientific Initiates $2 Billion Share Repurchase Agreement
- Share Repurchase Program: Boston Scientific has entered into an accelerated share repurchase agreement with JPMorgan to buy back $2 billion of its common stock, part of a previously authorized $5 billion program, reflecting the company's confidence in its stock value.
- Share Count and Value: The company will immediately receive approximately 30.4 million shares, representing 80% of the repurchase value based on the May 15 closing price, effectively reducing the number of shares in circulation and enhancing earnings per share.
- Financial Impact: This repurchase is expected to add $0.02 to the adjusted earnings per share by 2026, improving the financial guidance previously issued in April, indicating a proactive capital allocation strategy.
- Strategic Goals: By reducing the share count, Boston Scientific aims to deliver greater value to shareholders while maintaining resources to support its ongoing operational and strategic objectives, showcasing its long-term growth potential in the medical device sector.
See More
Boston Scientific and Others Face Stock Declines Amid Market Concerns
- Boston Scientific Stock Decline: Boston Scientific (BSX) shares fell to a 52-week low of $47.35 due to growing concerns over its U.S. Watchman heart-device franchise, with analysts cutting the price target to $70, reflecting anticipated slowdowns in 2026 and 2027 that negatively impact revenue and earnings.
- Lowe's Faces Weaker Growth Outlook: Lowe's (LOW) shares dropped to a new low of $207.55 as weaker growth expectations and a sluggish housing market weighed on prospects, despite first-quarter results beating estimates; high mortgage rates and inflation pressures continue to challenge the company.
- Conagra Brands New CEO Appointment: Conagra (CAG) shares hit a 52-week low of $13.10 amid investor concerns over growth prospects and profitability, as new CEO John Brase takes over, facing persistent inflation and weak consumer demand for packaged foods.
- Market Sentiment Shift: Despite BSX's stock dropping over 49%, retail sentiment on Stocktwits remains in the 'extremely bullish' territory, while Lowe's and CAG experience fluctuating sentiments due to market pressures, indicating cautious investor attitudes towards future performance.
See More
Boston Scientific Shares Hit 52-Week Low Amid Weak Growth Outlook
- Boston Scientific Stock Decline: Boston Scientific shares fell to a 52-week low of $48.13, experiencing a 16% weekly drop due to weak expectations for its Watchman heart device business, with management indicating that U.S. revenue may remain weak for the next two quarters, prompting analysts to lower price targets.
- Li Auto's Profitability Pressure: Li Auto reported weaker profits in its Q1 earnings, forecasting Q2 deliveries between 95,000 and 100,000 vehicles, reflecting soft demand and intense competition in China's EV market, leading Barclays to cut its price target from $18 to $14, implying nearly a 7% downside.
- Rollins Valuation Reset: Rollins reached a new low of $46.85 despite solid operating performance, as investors focused on valuation concerns, with Bernstein downgrading the stock and lowering its price target from $70 to $52, citing the potential negative impact of CFO Ken Krause's departure on profitability.
- Market Sentiment Shift: The stocks of Boston Scientific and Rollins have declined over 49% and 20% respectively this year, while Li Auto has shed over 11%, indicating a shift in investor confidence away from premium-priced growth stocks, with market sentiment changing from 'extremely bullish' to 'bullish'.
See More
Boston Scientific Shares Drop 15% Amid Analyst Downgrades
- Product Line Weakness: Boston Scientific acknowledged potential stagnation in sales of its Watchman heart implant line, contributing to a 15% drop in stock price this week, reflecting market concerns about future growth prospects.
- Analyst Downgrades: Wells Fargo analyst Lawrence Biegelsen downgraded Boston Scientific's rating from overweight to equal weight and reduced the price target from $75 to $55, indicating a pessimistic outlook on the company's future performance.
- Revenue Growth Guidance: Despite facing challenges, Boston Scientific maintained its guidance for organic revenue growth of 6.5% to 8% for 2026, demonstrating confidence in long-term growth potential.
- Increased Market Competition: Analysts noted that new drugs under development by pharmaceutical companies could heighten competitive pressure, particularly in other product categories like urology, further impacting the company's market position.
See More
Boston Scientific Shares Plummet Amid Weak Product Forecast
- Product Line Weakness: Boston Scientific CEO Mike Mahoney indicated at Bernstein's Annual Strategic Decisions Conference that sales of the Watchman heart implants may stagnate, with revenue expected to remain flat in both the current and following quarters, reflecting a shift in market demand away from standalone procedures, which could impact overall performance.
- Analyst Downgrades: Amid increasing pessimism, Wells Fargo analyst Lawrence Biegelsen downgraded the stock from overweight to equal weight and reduced the price target from $75 to $55, highlighting concerns over the new Watchman forecast and weakness in other product lines, such as urology.
- Significant Market Reaction: As of early Friday morning, Boston Scientific's shares had dropped by 15%, reflecting investor concerns about the company's future growth potential, particularly in the face of increasing competition that could affect its market share.
- Positive Long-Term Outlook: Despite short-term challenges, Boston Scientific maintained its guidance for organic revenue growth of 6.5% to 8% for 2026, indicating the company's long-term potential in the medical device sector, suggesting that investors may view this week's stock decline as an opportunity to acquire quality shares at a discount in a vibrant industry.
See More
Boston Scientific Faces Pressure Amid Weak Watchman Procedures
- Boston Scientific's Decline: CEO Michael Mahoney indicated that standalone Watchman procedures are weakening, leading to a 12% stock drop on Wednesday, hitting a two-year low of $50.04, which underscores the growth pressures in the medical device market.
- Li Auto's Loss Expectations: Li Auto's stock reached a 52-week low of $15.3 ahead of its earnings report, with analysts forecasting a RMB2.08 ($0.31) per-share loss, highlighting the intensified competition and price declines in China's EV market impacting profitability.
- BJ's Wholesale Earnings Outlook: BJ's Wholesale Club faced selling pressure as investors questioned its near-term earnings, with a 10-basis-point decline in merchandise margins in Q1, prompting DA Davidson to lower its price target to $105 while maintaining a 'Buy' rating, indicating challenges in the retail sector.
- Market Sentiment Shift: Despite Boston Scientific, Li Auto, and BJ's stocks hitting new 52-week lows, retail sentiment shifted from 'bearish' to 'bullish', reflecting investor expectations for potential rebounds in the near future.
See More
